SHKLY yields 5.27% · JNJ yields 2.13%● Live data
📍 SHKLY pulled ahead of the other in Year 1
Combined, SHKLY + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SHKLY + JNJ for your $10,000?
Sinotruk (Hong Kong) Limited, an investment holding company, engages in the research, development, manufacture, and sale of heavy-duty trucks (HDTs), medium-heavy duty trucks, light duty trucks (LDTs), buses, and related parts and components in Mainland China and internationally. The company operates through four segments: Heavy Duty Trucks, Light Duty Trucks and Others, Engines, and Finance. It offers specialty vehicles; industrial and construction machinery engines; HDT and LDT engines; and HDT key assemblies, such as gearboxes and various types of casting and forging, as well as cabins, axles, and steel frames. The company also provides axle and transmission parts and truck refitting services; deposit taking, borrowings, bank bills discounting, auto and supply chain financing, issue of bills, entrusted loans and investment, and customer credit services; loans; and consultation and strategic planning services. In addition, it imports and exports trucks and spare parts; manufactures and reproduces engines; and researches, develops, manufactures, and sells commercial vehicles. Sinotruk (Hong Kong) Limited serves infrastructure, construction, container transportation, logistic, mining, steel, chemical, and other industries. The company was incorporated in 2007 and is headquartered in Jinan, China. Sinotruk (Hong Kong) Limited is a subsidiary of China National Heavy Duty Truck Group Company Limited.
Full SHKLY Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.